Login

Alex Bokun

ORCID: 0000-0002-2622-6513
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5092932746
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Myeloid Leukemia Treatments
  • Immunodeficiency and Autoimmune Disorders
  • Acute Lymphoblastic Leukemia research

Janssen (United States)
 2023-2025

Johnson & Johnson (United States)
 2024-2025

Janssen Scientific Affairs (United States)
 2023-2024

 Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study
OPENALEX - Publications 
Nilanjan Ghosh Ruibin Wang Zhijie Ding Jinghua He Alex Bokun and 3 more Heena Mavani Zaina P. Qureshi Kerry A. Rogers

10.1182/blood-2023-187743 article EN Blood 2023-11-02
 Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation
OPENALEX - Publications 
Nilanjan Ghosh Ruibin Wang Zaina P. Qureshi Zhijie Ding Marie‐Hélène Lafeuille and 6 more Bruno Émond Bronwyn Moore Jinghua He Alex Bokun Heena Mavani Kerry A. Rogers

Ibrutinib, a once-daily Bruton's tyrosine kinase inhibitor (BTKi), is standard-of-care first-line (1L) treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphoma (SLL). Dosing flexibility (adjustment to daily dose <420 mg/day) ibrutinib can help prevent recurrence or worsening of adverse events, while maintaining long-term efficacy. This study compared time next (TTNT) among CLL/SLL in the United States initiating 1L single-agent at 420 mg/day (index date) and staying on...

10.1016/j.bneo.2024.100022 article EN cc-by-nc-nd Deleted Journal 2024-06-10
 Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation
OPENALEX - Publications 
Nilanjan Ghosh Zaina P. Qureshi Zhijie Ding Marie‐Hélène Lafeuille Bruno Émond and 6 more Priyanka Gogna Bronwyn Moore Patrick Lefèbvre Alex Bokun Heena Mavani Kerry A. Rogers

10.1182/blood-2023-186284 article EN Blood 2023-11-02
 CLL-481 Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review
OPENALEX - Publications 
John N. Allan Thomas J. Kipps Alex Bokun Rodrigo Maegawa Susan O’Brien

10.1016/s2152-2650(24)01285-0 article EN Clinical Lymphoma Myeloma & Leukemia 2024-08-26
 Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review
OPENALEX - Publications 
John N. Allan Thomas J. Kipps Alex Bokun Rodrigo Maegawa Susan O’Brien

10.1016/s2152-2650(24)00589-5 article EN Clinical Lymphoma Myeloma & Leukemia 2024-08-26
 Real-World Treatment Patterns and Clinical Outcomes Among Patients with Diffuse Large B-Cell Lymphoma in a US Healthcare Claims Database
OPENALEX - Publications 
Mazyar Shadman Jennifer S. Harper Alex Bokun Gloria HJ Graf Xiaoxiao Lu

10.1182/blood-2024-203289 article EN Blood 2024-11-05
 Estimating and Projecting the Number of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) By Treatment Lines in the United States
OPENALEX - Publications 
Xiaoxiao Lu Alex Bokun Chelsey Yang Yan Wang Weiye Chen and 2 more Jiamin Wang Narendranath Epperla

10.1182/blood-2024-198069 article EN Blood 2024-11-05
 Overall Survival of Patients with Chronic Lymphocytic Leukemia Treated with Frontline Bruton's Tyrosine Kinase Inhibitors: An Analysis of the United States Veterans Health Administration Database
OPENALEX - Publications 
Lindsey Fitzgerald Wasiulla Khan Alex Bokun Angela Lax Fan Mu and 4 more Yilu Lin Lizheng Shi Zaina P. Qureshi Solomon A. Graf

10.1182/blood-2024-201206 article EN Blood 2024-11-05
 P-422 Impact of early response and CXCR4 mutation status on progression-free survival with ibrutinib-based therapy in Waldenström macroglobulinemia: a post hoc analysis of the iNNOVATE trial
OPENALEX - Publications 
Jorge J. Castillo Shayna Sarosiek Andrew R. Branagan Alex Bokun Hillary M. Peltier and 3 more Vincent Girardi Michelle Pacia Steven P. Treon

10.1016/s2152-2650(23)02039-6 article EN Clinical Lymphoma Myeloma & Leukemia 2023-09-01
 Overall Survival Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients with High-Risk Molecular-Cytogenetic Features Treated with 1L Ibrutinib: A Comparative Effectiveness Study Using the Flatiron Health Data
OPENALEX - Publications 
John N. Allan Ran Tao Zhijie Ding Jinghua He Alex Bokun and 2 more Zaina P. Qureshi Susan O’Brien

10.1182/blood-2023-184318 article EN Blood 2023-11-02
 EE694 Evaluation of Healthcare Resource Utilization and Cost Among First-Line Patients Receiving Ibrutinib Vs Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Commercial Claims Database Analysis
OPENALEX - Publications 
Benyam Muluneh Jinghua He Zhijie Ding Alex Bokun Zaina P. Qureshi

10.1016/j.jval.2023.09.959 article EN Value in Health 2023-12-01
 EE70 Real-World Comparison of Healthcare Resource Utilization and Costs Between Patients with Chronic Lymphocytic Leukemia Treated with First-Line Ibrutinib or Acalabrutinib
OPENALEX - Publications 
Kerry A. Rogers Zaina P. Qureshi Zhijie Ding Bruno Émond Priyanka Gogna and 3 more Marie‐Hélène Lafeuille Alex Bokun Michael G. Fradley

10.1016/j.jval.2023.09.342 article EN Value in Health 2023-12-01
Coming Soon ...